Erin Zagadailov

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Mitapivat versus Placebo for Pyruvate Kinase Deficiency

Hanny Al‐Samkari, F. Galactéros, Andreas Glenthøj et al. · New England Journal of Medicine · 2022 · 94 citations · Full text

Medicine, Hematology, Pharmacology +13

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom

Paul J. Bröckelmann, Suzanne McMullen, Jake Wilson et al. · British Journal of Haematology · 2018 · 54 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.

Erin Zagadailov, Michael J. Fine, Alan L. Shields · PubMed · 2013 · 53 citations

Pharmacy, Oncology, Pharmaceutical Policy +17

Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial

Andreas Glenthøj, Eduard J. van Beers, Hanny Al‐Samkari et al. · The Lancet Haematology · 2022 · 48 citations

Medicine, Hematology, Pharmacology +12